Lab Test

Saccharomyces cerevisiae Ab, IgG and IgA

Test Codes

EPIC: LAB7987, Beaker: XSACA, ARUP: 0050564

Department

Send Outs

Specimen Collection Criteria

Collect (preferred specimen): One Gold-top SST tube.

Physician Office/Draw Specimen Preparation

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells within 2 hours of collection. Transfer serum to plastic transport tube and refrigerate (2-8°C or 36-46°F).

Preparation for Courier Transport

Transport: 0.5 mL serum, refrigerated (2-8°C or 36-46°F). (Minimum: 0.3 mL)

Rejection Criteria

  • Grossly lipemic specimen.
  • Grossly hemolyzed specimen.
  • Contaminated specimen.
  • Heat inactivated specimen.
  • Specimens not collected and processed as indicated.

In-Lab Processing

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells within 2 hours of collection. Transfer serum to plastic transport tube and refrigerate (2-8°C or 36-46°F).

Transport: 0.5 mL serum, refrigerated (2-8°C or 36-46°F). (Minimum: 0.3 mL)

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): 48 hours
Refrigerated (2-8°C or 36-46°F): 14 days
Frozen (-20°C/-4°F or below): 1 year

Specimen Storage in Department Prior to Disposal:

Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.

Laboratory

Sent to ARUP Laboratories in Salt Lake City, UT.

Performed

Sunday – Saturday
Results available in 1-2 days.

Reference Range

By report.

Test Methodology

Semi Quantitative Enzyme-Linked Immunosorbent Assay (ELISA).

Clinical Utility

This test aids in differentiating Crohn's disease from ulcerative colitis.

Crohn's disease and ulcerative colitis are two types of inflammatory bowel disease. Crohn's disease usually affects the small intestines, however it can affect any part of the digestive tract and may be segmental. Ulcerative colitis causes inflammatory changes and ulcerations in the colon and rectum. Signs and symptoms of Crohn's disease and ulcerative colitis can be similar and diagnosis may be difficult.

Recent studies have shown that anti-saccharomyces cerevisiae antibodies (ASCA) are more likely to occur in Crohn's disease than in ulcerative colitis or healthy controls. One study found the presence of both IgG and IgA ASCA was 100% specific for Crohn's disease, however not all patients with Crohn's disease have these antibodies.

A large proportion (approximately 70%) of patients with ulcerative colitis have been found to be positive for P-ANCA (perinuclear antineutrophilic cytoplasmic antibodies). Use of both ASCA and ANCA could assist in differentiating ulcerative colitis from Crohn's disease. The following table summarizes likelihood of positivity in ASCA and ANCA testing in Crohn's disease and ulcerative colitis.

  ASCA IgG ASCA IgA P-ANCA
Crohn's disease 80% positive 35% positive Less than 20% positive
Ulcerative colitis 20% positive Less than 1% positive 70% positive

CPT Codes

86671 x 2.

Contacts

Last Updated

10/8/2023

Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.